The effect of selective low-density lipoprotein apheresis on plasma lipoperoxides and antioxidant vitamins in familial hypercholesterolemic patients.
Familial hypercholesterolemia (FH) is an autosomal dominant genetic disorder characterized by a lifelong elevation in the concentration of low-density lipoprotein (LDL) bound cholesterol in blood by cholesterol deposits and by early coronary artery disease. The LDL apheresis technique has been introduced with the goal of reducing LDL cholesterol levels, thereby preventing the development of atherosclerosis. The literature on LDL apheresis reports 2 different facets, the therapeutic aspect associated with the lessening of LDL concentration and the initiation of a peroxidation process associated with the biocompatibility of the artificial membrane. Lipid and protein peroxidation gives rise to toxic and atherogenic hydroperoxide, mostly lipid hydroperoxides, and derivative compounds, which may offset the benefit of the procedure. In this paper, plasma hydroperoxide levels are determined along with the elevation of the serum and LDL antioxidant status in hypercholesterolemic patients before and following repeated LDL apheresis sessions. Hydroperoxide concentration has been expressed both in terms of plasma volume and LDL concentration. A highly significant increase in LDL lipid hydroperoxides is demonstrated when expressed in terms of LDL concentration and is associated with the LDL apheresis procedure. The usefulness of antioxidant supplementation in LDL apheresis is discussed.
Baricchi
R
R
Servizio d'Immunoematologia e Trasfusionale, Arcispedale S. Maria Nuova Azienda Ospedaliera, Reggio Emilia, Pavia, Italy.
Pizzala
R
R
Cacciavillani
G
G
Rivasi
P
P
Tomasi
A
A
D000328:Adult; D000975:Antioxidants / Q000032:analysis* / Q000627:therapeutic use; D001672:Biocompatible Materials; D001781:Blood Component Removal / Q000295:instrumentation / Q000379:methods; D016022:Case-Control Studies; D002784:Cholesterol / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood / Q000378:metabolism; D003324:Coronary Artery Disease / Q000209:etiology / Q000517:prevention & control; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000628:therapy*; D015227:Lipid Peroxidation; D008054:Lipid Peroxides / Q000097:blood*; D008077:Lipoproteins, LDL / Q000097:blood*; D008297:Male; D008567:Membranes, Artificial; D008875:Middle Aged; D010545:Peroxides / Q000097:blood; D014280:Triglycerides / Q000097:blood; D014801:Vitamin A / Q000097:blood; D014810:Vitamin E / Q000097:blood* / Q000627:therapeutic use; D019207:beta Carotene / Q000097:blood* / Q000627:therapeutic use
D000975:Antioxidants; D001672:Biocompatible Materials; D008078:Cholesterol, LDL; D008054:Lipid Peroxides; D008077:Lipoproteins, LDL; D008567:Membranes, Artificial; D010545:Peroxides; D014280:Triglycerides; D019207:beta Carotene; D014801:Vitamin A; D014810:Vitamin E; D002784:Cholesterol